β-Galactoside α2,6-sialyltranferase 1 promotes transforming growth factor-β-mediated epithelial-mesenchymal transition

J Biol Chem. 2014 Dec 12;289(50):34627-41. doi: 10.1074/jbc.M114.593392. Epub 2014 Oct 24.

Abstract

β-Galactoside α2,6-sialyltranferase 1 (ST6GAL1) catalyzes the addition of terminal α2,6-sialylation to N-glycans. Increased expression of ST6GAL1 has been reported in diverse carcinomas and highly correlates with tumor progression. Here, we report that St6gal1 transcription and α2,6-sialylated N-glycans are up-regulated during TGF-β-induced epithelial-mesenchymal transition (EMT) in GE11 cells, requiring the Sp1 element within the St6gal1 promoter. Knockdown of St6gal1 strongly suppressed TGF-β-induced EMT with a concomitant increase in E-cadherin expression, a major determinant of epithelial cell adherens junctions. Conversely, overexpression of ST6GAL1 increased the turnover of cell surface E-cadherin and promoted TGF-β-induced EMT. Overexpressing β-galactoside α2,3-sialyltranferase 4 had little influence on EMT, indicating specificity for α2,6-sialylation. The basal mesenchymal phenotype of MDA-MB-231 human breast cancer cells was partially reversed by ST6GAL1 silencing. Moreover, ST6GAL1 knockdown inhibited the phosphorylation of Akt, but not Smad2, suggesting that ST6GAL1 contributes to EMT through a non-Smad signaling pathway. Taken together, our data indicate that ST6GAL1 promotes TGF-β-dependent EMT as well as maintenance of the mesenchymal state by growth signaling, providing a plausible mechanism whereby up-regulated ST6GAL1 may promote malignant progression.

Keywords: Cadherin; Cell Migration; Epithelial-Mesenchymal Transition (EMT); N-Linked Glycosylation; Sialyltransferase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / genetics
  • Antigens, CD / metabolism*
  • Binding Sites
  • Breast Neoplasms / pathology
  • Cadherins / metabolism
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Disease Progression
  • Epithelial-Mesenchymal Transition / drug effects*
  • Gene Knockdown Techniques
  • Gene Silencing
  • Humans
  • Phenotype
  • Promoter Regions, Genetic / genetics
  • Sialyltransferases / deficiency
  • Sialyltransferases / genetics
  • Sialyltransferases / metabolism*
  • Sp1 Transcription Factor / metabolism
  • Transcriptional Activation / drug effects
  • Transforming Growth Factor beta / pharmacology*
  • Up-Regulation / drug effects

Substances

  • Antigens, CD
  • Cadherins
  • Sp1 Transcription Factor
  • Transforming Growth Factor beta
  • Sialyltransferases
  • ST6GAL1 protein, human